Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALD-101 Adjuvant Therapy in UCBT for Inborn Errors of Metabolism
NCT00654433Phase 3Terminated
- Sponsor
- Aldagen
- Start
- Mar 2008
- Primary completion
- Jul 2011
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ALD-101 in Inborn errors of metabolism (IEM), sponsored by Aldagen. Primary endpoint: Time to Platelet Engraftment at 180 Days. Started Mar 2008; status: terminated.
02
Drugs
ALD-101
03
Conditions
Inborn errors of metabolism (IEM)
Beyond the preview
Go deeper on NCT00654433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00654433.